加载中
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
前收盘价
US$21.08
+US$0.52 · +2.53%
盘中时间采用ET。市场数据可能有所延迟。
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$21.08
52周区间
当前US$21.08
盘中时间采用ET。市场数据可能有所延迟。
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$21.08
52周区间
当前US$21.08
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$50.00
上涨空间 137.19%评级样本有限，仅3项
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM2565.27万0.03%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1508.02万0.15%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Russell 2000 ETFVTWO864.8万0.05%180亿 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO620.71万0.05%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF605.57万0.01%954亿 USD0.05%US$235+0.80%
Schwab U.S. Small-Cap ETFSCHA541.82万0.02%218.24亿 USD0.03%US$32.79+0.40%
iShares Core S&P Total U.S. Stock Market ETFITOT146.49万0.00%980.88亿 USD0.03%US$169.66+0.64%
Vanguard Russell 2000 Growth ETFVTWG113.48万0.06%17亿 USD0.06%US$260.49+0.91%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Core S&P Total U.S. Stock Market ETFITOTVanguard Russell 2000 Growth ETFVTWGAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
